Clinical Trials Browser

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00006478 2023-09-18

Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

Phase 2 Terminated

19 enrolled 4 charts

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT05284214 2023-09-15

SALIENT

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT00004197 2023-09-07

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase 2 Completed

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05794659 2023-07-20

Cornerstone4

Phase 2 Not yet recruiting

98 enrolled

Gynecologic

Advanced Ovarian Cancer

NCT00005962 2023-06-22

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

NCT00014508 2023-06-22

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Phase 2 Completed

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04703426 2023-05-22

Sargramostim (GM-CSF) + PD-1

Phase 2 Withdrawn

Dermatologic

Melanoma

NCT00005780 2023-01-31

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

Phase 2 Completed

26 enrolled 18 charts

Lymphoid

Lymphoma, Mantle-Cell

NCT02978222 2022-12-15

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Phase 2 Terminated

120 enrolled 12 charts

Gynecologic

Ovarian Neoplasms

NCT01767194 2022-10-24

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Phase 2 Completed

73 enrolled 12 charts

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT01700673 2022-10-18

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Phase 2 Completed

25 enrolled 13 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05075122 2022-03-09

FOCUS

Phase 2 Unknown

75 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02873819 2022-03-08

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Phase 2 Completed

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02703714 2022-01-25

Pembrolizumab and GM-CSF in Biliary Cancer

Phase 2 Completed

42 enrolled 19 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT00488592 2021-07-12

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Phase 2 Completed

10 enrolled 7 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00562328 2020-04-08

Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

Phase 2 Completed

33 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00524277 2020-03-30

Vaccine Therapy in Treating Patients With Breast Cancer

Phase 2 Completed

456 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01363206 2020-03-19

GIPI

Phase 2 Completed

29 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis

NCT00514215 2020-03-05

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

Phase 2 Completed

8 enrolled 5 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT00343109 2020-02-12

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

Phase 2 Completed

38 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

Clinical Trials

Testing the SurVaxM Vaccine for Lung Cancer Prevention

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

GM-CSF With Post-Transplant Cyclophosphamide

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Metastatic Solid Cancer Clinical Trial

Conerstone3

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma

I-ATTAC

Vaccine Therapy in Treating Patients With Multiple Myeloma

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

NIPU

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

HER3+

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

LUNGVAC

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant

Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma

SALIENT

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Cornerstone4

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Sargramostim (GM-CSF) + PD-1

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

FOCUS

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

Pembrolizumab and GM-CSF in Biliary Cancer

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

Vaccine Therapy in Treating Patients With Breast Cancer

GIPI

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer